Related references
Note: Only part of the references are listed.Thera-SAbDab: the Therapeutic Structural Antibody Database
Matthew I. J. Raybould et al.
NUCLEIC ACIDS RESEARCH (2020)
Modeling and mitigation of high-concentration antibody viscosity through structure-based computer-aided protein design
James R. Apgar et al.
PLOS ONE (2020)
A single molecular descriptor to predict solution behavior of therapeutic antibodies
Jonathan S. Kingsbury et al.
SCIENCE ADVANCES (2020)
Five computational developability guidelines for therapeutic antibody profiling
Matthew I. J. Raybould et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology
Gaurav Bajaj et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data
Hannah M. Jones et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma
Maria Gabriella Matera et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
DrugBank 5.0: a major update to the DrugBank database for 2018
David S. Wishart et al.
NUCLEIC ACIDS RESEARCH (2018)
Current progress in innovative engineered antibodies
William R. Strohl
PROTEIN & CELL (2018)
Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia
Mita Kuchimanchi et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2018)
Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics
Lindsay B. Avery et al.
MABS (2018)
Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies
Arif Jetha et al.
MABS (2018)
AggScore: Prediction of aggregation-prone regions in proteins based on the distribution of surface patches
Kannan Sankar et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2018)
Biophysical properties of the clinical-stage antibody landscape
Tushar Jain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Computational tool for the early screening of monoclonal antibodies for their viscosities
Neeraj J. Agrawal et al.
MABS (2016)
Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies
Lindsay B. Avery et al.
MABS (2016)
Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics
Daniela Bumbaca Yadav et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice
Ryan L. Kelly et al.
MABS (2015)
The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies
Amita Datta-Mannan et al.
MABS (2015)
Rational design of viscosity reducing mutants of a monoclonal antibody: Hydrophobic versus electrostatic inter-molecular interactions
Pilarin Nichols et al.
MABS (2015)
Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
Angela Schoch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
Amrita V. Kamath et al.
PHARMACEUTICAL RESEARCH (2015)
In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability
Vikas K. Sharma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
Shahneen K. Sandhu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Different Adaptations of IgG Effector Function in Human and Nonhuman Primates and Implications for Therapeutic Antibody Treatment
Max Warncke et al.
JOURNAL OF IMMUNOLOGY (2012)
Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration
Yanan Zheng et al.
MABS (2012)
A strategy for risk mitigation of antibodies with fast clearance
Isidro Hoetzel et al.
MABS (2012)
Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study
Zhenhua Xu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors
David E. Gerber et al.
CLINICAL CANCER RESEARCH (2011)
Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody
Deborah A. Smith et al.
CLINICAL PHARMACOKINETICS (2011)
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data What have we learned?
Rong Deng et al.
MABS (2011)
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Nathanael L. Dirks et al.
CLINICAL PHARMACOKINETICS (2010)
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Ron J. Keizer et al.
CLINICAL PHARMACOKINETICS (2010)
LowModeMD-Implicit Low-Mode Velocity Filtering Applied to Conformational Search of Macrocycles and Protein Loops
Paul Labute
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2010)
Reduced elimination of IgG antibodies by engineering the variable region
T. Igawa et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Design of therapeutic proteins with enhanced stability
Naresh Chennamsetty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Protonate3D: Assignment of ionization states and hydrogen coordinates to macromolecular structures
Paul Labute
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2009)
Species selection considerations for preclinical toxicology studies for biotherapeutics
Jeanine L. Bussiere
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Very fast empirical prediction and rationalization of protein pKa values
H Li et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2005)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
